The treatment of patients with low tumour burden and/or slow growing disease.
In the evaluation of the wide range of novel therapeutics which have been developed, investigators do not have to be tied to the current paradigm of demonstrating additive efficacy to first line combination therapy. The addition of new agents to FOLFOX regimens has proved a high hurdle at which many...
Príomhchruthaitheoir: | Maughan, T |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2011
|
Míreanna comhchosúla
Míreanna comhchosúla
-
The response of fast-, medium- and slow-growing chickens to a low protein diet
de réir: Darina Chodová, et al.
Foilsithe / Cruthaithe: (2021-03-01) -
Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?
de réir: Magaly Zappa, et al.
Foilsithe / Cruthaithe: (2017-02-01) -
STING signalling compensates for low tumour mutation burden to drive anti-tumour immunityResearch in context
de réir: Jiayi Tan, et al.
Foilsithe / Cruthaithe: (2024-03-01) -
Slow growing of Stieltjes integrals of monotone functions
de réir: M. V. Zabolotskyj, et al.
Foilsithe / Cruthaithe: (2013-01-01) -
Cassava residues in the diet of slow-growing broilers
de réir: Silvia Silva VIEIRA, et al.
Foilsithe / Cruthaithe: (2022-09-01)